EKF Diagnostics gets cash boost from Admiral sale

Friday, Dec 24 2010 by
EKF Diagnostics gets cash boost from Admiral sale

EKF Diagnostics (LON:EKF) , the AIM listed point-of-care diagnostics business, has agreed a deal to sell its remaining rights in the Admiral sportswear brand for around £830,000 in cash. The deal takes the total consideration for the sale of Admiral in all territories in 2010 to in excess of £1.8m.

EKF has spent much of 2010 re-focusing its strategy on in-vitro diagnostics having previously specialised in sports marketing under the guise of International Brand Licensing plc. The group firth embarked on a disposal strategy back in 2005 and has since raised approximately £10m through the disposal of Mountain Equipment, Admiral and various sponsorship terminations.

Late last year the group changed its name to EKF and said it intended to use International Brand Licensing as a vehicle to build a group focused on the in-vitro diagnostics industry, through acquisition. Those deal began flowing in June with the acquisition of EKF-diagnostic GmbH, which was followed by Quotient Diagnostics and Argutus Medical.

Julian Baines, the chief executive of EKF, said: “Since my arrival at EKF Plc and the re-focussing of the group into a vitro diagnostic's business, we have sought the disposal of non-core assets and I am delighted that we have now concluded the sale of the remaining Admiral sportswear territories, the net proceeds will be used to further enhance the growth of our underlying business.”

Unlock this article instantly by logging into your account

Don’t have an account? Register for free and we’ll get out your way


As per our Terms of Use, Stockopedia is a financial news & data site, discussion forum and content aggregator. Our site should be used for educational & informational purposes only. We do not provide investment advice, recommendations or views as to whether an investment or strategy is suited to the investment needs of a specific individual. You should make your own decisions and seek independent professional advice before doing so. Remember: Shares can go down as well as up. Past performance is not a guide to future performance & investors may not get back the amount invested. ?>

Do you like this Post?
1 thumb up
0 thumbs down
Share this post with friends

EKF Diagnostics Holdings plc is engaged in developing, manufacturing and supplying of products and services into the in-vitro diagnostic (IVD) market place. The Company manufactures and sells diagnostic instruments, reagents and certain ancillary products. The Company's point-of-care range includes hemoglobin analyzers, HbA1c analyzers and glucose analyzers for use in the screening, monitoring and diagnosis of patients, as well as rapid tests for pregnancy and common infectious diseases. The Company's Central Laboratory division includes a range of products for use in both large and small laboratory facilities. Its subsidiary, EKF Life Sciences, provides bulk diagnostic enzyme manufacturing and fermentation services. EKF Life Sciences specializes in producing enzymes, including Salicylate Hydroxylase and Beta-Hydroxybutyrate Dehydrogenase. Its products include Quo-Test A1c, Biosen C-Line and Biosen S-Line, STAT-Site M B-HB analyzer, sTNFR1 biomarker test kits and Altair 240. more »

LSE Price
Mkt Cap (£m)
P/E (fwd)
Yield (fwd)

  Is LON:EKF fundamentally strong or weak? Find out More »

Please subscribe to submit a comment

About Stockopedia News

Stockopedia News

Stockopedia News Bulletins aim to report on stories and companies that are relevant to and popular with online investors.  It's a free service provided to registered users of Stockopedia. 

Stock Picking Tutorial Centre

Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis